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Abstract 
Background: The heart requires constant sources of energy mostly from free fatty acids (FFA) and glucose. The 
alteration in myocardial substrate metabolism occurs in the heart of diabetic patients, but its specific association with 
other metabolic variables remains unclear. We aimed to evaluate glucose uptake in hearts of subjects with normal 
glucose tolerance (NGT), prediabetes, and type 2 diabetes mellitus (T2DM) using [18F]‑fluorodeoxyglucose‑positron 
emission tomography (18FDG‑PET) in association with visceral and subcutaneous adiposity, and metabolic laboratory 
parameters.
Methods: A total of 346 individuals (NGT, n = 76; prediabetes, n = 208; T2DM, n = 62) in a health promotion center 
of a tertiary hospital were enrolled. The fasting myocardial glucose uptake, and visceral and subcutaneous fat areas 
were evaluated using 18FDG‑PET and abdominal computed tomography, respectively.
Results: Myocardial glucose uptake was significantly decreased in subjects with T2DM compared to the NGT or pre‑
diabetes groups (p for trend = 0.001). Multivariate linear regression analyses revealed that visceral fat area (β = −0.22, 
p = 0.018), fasting FFA (β = −0.39, p < 0.001), and uric acid levels (β = −0.21, p = 0.007) were independent deter‑
minants of myocardial glucose uptake. Multiple logistic analyses demonstrated that decreased myocardial glucose 
uptake (OR 2.32; 95 % CI 1.02–5.29, p = 0.045) and visceral fat area (OR 1.02, 95 % CI 1.01–1.03, p = 0.018) were associ‑
ated with T2DM.
Conclusions: Our findings indicate visceral adiposity is strongly associated with the alteration of myocardial glucose 
uptake evaluated by 18FDG‑PET, and its association further relates to T2DM.
Keywords: Visceral fat, Myocardium, Type 2 diabetes mellitus, Positron emission tomography, Insulin resistance
© 2015 Kim et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  edgo@yuhs.ac; yunmijin@yuhs.ac 
†Gyuri Kim and Kwanhyeong Jo contributed equally to the study
1 Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Yonsei University College of Medicine, 50‑1, Yonsei‑ro, 
Seodaemun‑gu, Seoul 03722, Republic of Korea
3 Department of Nuclear Medicine, Yonsei University College of Medicine, 
50‑1, Yonsei‑ro, Seodaemun‑gu, Seoul 03722, Republic of Korea
Full list of author information is available at the end of the article
Page 2 of 10Kim et al. Cardiovasc Diabetol  (2015) 14:148 
Background
Type 2 diabetes mellitus (T2DM) is a chronic and 
increasing worldwide disorder that is characterized by 
hyperglycemia, insulin resistance, and dyslipidemia, and 
its independent association with dysfunctional adipos-
ity, such as excess visceral fat has been reported [1, 2]. 
Several studies demonstrated that T2DM also provokes 
long-term dysfunction and damage to various organs 
including the eye, kidney, and heart [3]. In general, the 
heart requires constant sources of energy that mainly 
include free fatty acids (FFA) and glucose for continu-
ous pumping, and has high flexibility with regards to the 
energy substrate metabolism [4]. However, in the T2DM 
heart, alterations in myocardial substrate metabolism, 
characterized by increased myocardial fatty acid metab-
olism and concurrently decreased glucose metabolism, 
have been reported [4–6].
Positron emission tomography (PET) can monitor 
increased uptake of the glucose analogue [18F]-fluorode-
oxyglucose (18FDG), that is taken up by tissues via glucose 
transporter proteins [7]. Recent studies have reported 
that disturbances of carbohydrate, fat, and protein 
metabolism altered biodistribution of 18FDG in patients 
with T2DM [8]. In addition, regarding myocardial insulin 
sensitivity, myocardial glucose uptake can differ accord-
ing to the status of whole body insulin resistance, such as 
prediabetes and T2DM, compared with normal glucose 
tolerance (NGT) controls. However, few studies have 
investigated the relationship(s) of myocardial glucose 
uptake using PET, adiposity, and other metabolic profiles 
in subjects with NGT, prediabetes, and T2DM [8–10].
In the current study, we therefore investigated myo-
cardial glucose uptake using [18F]-fluorodeoxyglucose-
positron emission tomography (18FDG-PET), and 
characterized its associations with various clinical and 
laboratory parameters according to glycemic status.
Methods
Study population
Between January, 2008 and July, 2014, asymptomatic 387 
individuals who visited the health promotion center in 
Severance Hospital for comprehensive health examina-
tions were included on this study. Patients with present 
abnormal renal or hepatic functions, history of myocar-
dial infarction, and heart failure were excluded (n = 20). 
Furthermore, 23 subjects with coronary artery calcium 
score (CACS) over 400 evaluated by coronary computed 
tomography angiography were excluded for subclinical 
coronary artery disease [11]. Finally, we studied a total 
of 346 individuals including 76 healthy subjects with 
NGT, 208 subjects with prediabetes such as impaired 
fasting tolerance, impaired glucose tolerance, and 62 
subjects with T2DM, as defined by the 2014 revision 
of the American Diabetes Association guidelines [12]. 
The protocol of this study adhered to the tenets of the 
Declaration of Helsinki, was approved by the Institu-
tional Review Board (IRB No. 4-2015-0038) of Severance 
Hospital.
Measurement of clinical and laboratory parameters
All individuals provided data including personal medical 
history, drinking and smoking habits, and use of medica-
tion at the time of their enrolment. Drinking habits were 
categorized according to self-reports as noncurrent or 
current, and smoking habits as never, ex-smoker, and 
current smoker. Body mass index (BMI) was defined as 
weight divided by the square of the height (kg/m2). Blood 
pressure was obtained by averaging the results of three 
blood pressure recordings in the sitting position, each 
after at least 5 min of rest. Blood samples were collected 
from each participant after overnight fasting. The fasting 
and 2  h postprandial glucose, insulin, FFA, and triglyc-
erides (TG) were measured. Plasma glucose was mea-
sured using the glucose oxidase method. Plasma total 
choles-terol, TG, high density lipoprotein (HDL) choles-
terol, FFA, lipoprotein(a), and uric acid were assayed us-
ing a Hitachi 7600 Auto Analyzer (Hit-achi Instruments 
Service, Tokyo, Japan). Low density lipopro-tein (LDL) 
cholesterol was calculated using the Friedewald equa-
tion (LDL cholesterol [mg/dL]  =  total cholesterol [mg/
dL] − HDL cholesterol [mg/dL] − TG [mg/dL]/5). Serum 
glycated albumin was determined using an enzymatic 
method as previously described [13]. HbA1c was meas-
ured by high-performance liquid chromatography using a 
Variant™ II Turbo (Bio-Rad Laboratories, Hercules, CA, 
USA). Homeostasis Model Assessment of Insulin Resist-
ance (HOMA-IR) was calculated using the following for-
mula: (fasting plasma insulin [μU/mL] ×  fasting plasma 
glucose [mg/dL]/405) [14]. An index of Adipose tissue 
Insulin Resistance (Adipo-IR) was calculated using the 
following formula: (fasting plasma FFA [mmol/L] × fast-
ing plasma insulin [pmol/L]) [15].
Abdominal adipose tissue areas and coronary artery 
calcification score (CACS) by multislice computed 
tomography (CT)
The abdominal adipose tissue areas were determined by 
either a dual source 128 slice CT scanner (Somatom Def-
inition Flash, Siemens Healthcare, Forchheim, Germany) 
or a 64 slice CT scanner (Somatom Sensation 64, Sie-
mens Healthcare) with a slice thickness of 3 mm, a tube 
voltage of 120 kV, 150 effective mAs, 1.0 pitch, and a 0.5 s 
rotation time. Visceral adipose tissue, and subcutaneous 
adipose tissue areas at the L3–L4s vertebral disc space 
in a supine position were measured using the Aquarius 
iNtuition Viewer software, version 4.4.11 (Terarecon, San 
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Mateo, CA, USA). The fat area was identified using atten-
uation values between −190 and −30 Hounsfield units. 
For CACS, a prospective electrocardiography-gated scan 
was performed with a slice-width of 3 mm, a tube voltage 
of 100 kV, 80 mAs, collimation 32 × 1.2, and table feed of 
34.5  mm. The images were reconstructed with the B36f 
kernel (b36f ), and CACS was calculated with the use of 
CAC analysis software (Cascore, Siemens, Germany) 
using the Agatstone method [16].
18FDG‑PET and image analysis
Whole body PET-CT was performed using either one 
of two combined PET-CT scanners: a Biograph True-
Point 40 (Siemens Medical Solutions, Hoffman Estates, 
IL, USA) or a Discovery 600 (General Electric Medical 
Systems, Milwaukee, WI, USA). All patients fasted for at 
least 8 h, and blood glucose levels were recorded before 
the injection of 18FDG. Approximately 5.5 mBq of 18FDG 
per kilogram of body weight were administered intrave-
nously. PET-CT scanning was conducted from the skull 
base to the mid-thigh at 60  min after injection. For the 
Biograph TruePoint 40 scanner, a spiral CT scan with a 
0.5  s rotation time, 35 mA, 120 kVp, and 5 mm section 
width with arms raised, was used. For the Discovery 
600 scanner, a spiral CT scan with a 0.8 s rotation time, 
60  mA, 120  kVp, 3.75  mm section thickness, 1.25  mm 
collimation, and 27.5  mm table feed per rotation with 
arms raised, was used. PET image acquisition followed 
CT scanning using the following parameters: 2.5 min per 
bed position of 21.6  cm in a three-dimensional acquisi-
tion mode (Biograph TruePoint 40) or 2  min per bed 
position of 15.7  cm in a three-dimensional acquisition 
mode (Discovery 600). Reconstructions of PET images 
were acquired using a 128  ×  128 matrix with ordered 
subset expectation maximization and attenuation 
correction.
The standardized uptake value (SUV) was calcu-
lated by nuclear medicine experts who were blind to 
the subjects’ clinical and laboratory data as follows: 
SUV =  (decay-corrected activity [kBq] per mL of tissue 
volume)/(injected 18FDG activity [kBq]/body mass [g]). 
Two-dimensional regions of interest (ROIs) were drawn 
through the transaxial images to measure the SUVmax 
of the left ventricular myocardium. Patients with strik-
ing focal FDG uptake in the left ventricle that could be 
caused by ischemic change were excluded [17]. We also 
obtained the liver SUV, which was quite stable over time, 
from the circular ROI along the periphery of the right 
lobe, 1  cm from the margin by averaging at least three 
times of these values. The values of SUV of the heart to 
liver FDG uptake ratio (SUVHeart/SUVLiver) were used to 
estimate the myocardial glucose uptake to minimize vari-
ability [18–20].
Statistical analysis
All continuous variables were expressed as the 
mean  ±  standard deviation, and categorical variables 
were expressed as proportions. Differences were ana-
lysed using the analysis of variance (ANOVA) for con-
tinuous variables and the Chi-square test for categorical 
variables. Comparisons of myocardial glucose uptake 
relative to the status of diabetes were calculated with the 
Jonckheere–Terpstra trend test. Pearson’s correlation 
coefficients were calculated to examine the relationships 
between myocardial glucose uptake and metabolic vari-
ables. Multiple linear regression analysis was performed 
to determine the independent relationships of the stud-
ied variables, and standardized β was represented as the 
coefficient β. The odds ratios (ORs) and 95 % confidence 
intervals (CIs) for the factors associated with T2DM were 
calculated using the multiple logistic regression analy-
sis. In the Pearson’s correlation, multiple linear regres-
sion, and multiple logistic regression analysis, values 
of myocardial glucose uptake (SUVHeart/Liver) were log-
transformed to achieve normal distribution. A value of 
p < 0.05 was considered statistically significant. Statistical 
analyses were performed using PASW Statistics software, 
version 20.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
For all subjects, the mean age of patients was 
56.9 ±  10.7  years and 53.1  % were women. The average 
BMI was 24.1 ±  3.4  kg/m2, which was within the over-
weight range of BMI (23.0–24.9  kg/m2) by Asia–Pacific 
BMI cutoffs [21]. Of these 346 subjects, the total num-
ber of patients who were taking one or more antihyper-
tensive medications were 75 (22.0  %) and lipid lowering 
medications were 63 (18.4 %; statin, n = 57, 16.5 %; fenofi-
brate, n = 4, 1.2 %; omega-3, n = 4, 1.2 %). Among T2DM 
patients, oral antidiabetic drug users and insulin users 
were 32.8 and 8.2  %, respectively. The baseline charac-
teristics of participants by glycemic status are shown in 
Table 1. Subjects with prediabetes or T2DM tended to be 
older, to have higher systolic blood pressure, to be more 
obese, and to have metabolically unhealthy factors com-
pared to subjects with NGT. Subjects with prediabetes or 
T2DM were more likely to have higher levels of uric acid 
and larger visceral fat areas compared to subjects with 
NGT.
Myocardial glucose uptake for NGT, prediabetes, and T2DM 
subjects
Figure  1 shows the myocardial glucose uptake for sub-
jects, based upon the glycemic status. Compared to the 
NGT or prediabetes groups, myocardial glucose uptake 
was significantly decreased in patients with T2DM 
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(mean myocardial glucose uptake; NGT, prediabetes, 
and T2DM; 1.94, 1.58, and 1.17, respectively; p for trend 
<0.001; Fig.  2). The proportion of the highest tertile of 
myocardial glucose uptake was significantly lower in sub-
jects with T2DM than those in subjects with NGT and 
prediabetes (p = 0.013, data not shown).
Table 1 Characteristics of the study subjects
Data are expressed as mean ± standard deviation of the mean or n (%)
Adipo-IR index of adipose tissue insulin resistance, BMI body mass index, DBP diastolic blood pressure, DPP4 dipeptidyl peptidase-4, FFA free fatty acids, HOMA-IR 
Homeostasis model assessment of insulin resistance, HDL high density lipoprotein, IFG impaired fasting glucose, LDL low density lipoprotein, NA not applicable, 
NGT normal glucose tolerance, SBP systolic blood pressure, T2DM type 2 diabetes, TG triglycerides, TyG the product of fasting triglycerides and glucose levels, TZD 
thiazolidinedione
Variables NGT
(n = 76)
Prediabetes
(n = 208)
T2DM
(n = 62)
p
Age (years) 50.1 ± 10.9 57.9 ± 9.1 61.7 ± 11.5 <0.001
Female sex 38 (50.0) 101 (48.6) 37.1 (62.9) 0.233
Current drinker 30 (40.5) 110 (53.9) 27 (44.3) 0.099
Current smoker 11 (14.9) 27 (13.2) 8 (13.1) 0.934
SBP (mmHg) 117.7 ± 13.3 121.5 ± 14.3 127.9 ± 12.9 <0.001
DBP (mmHg) 74.9 ± 10.8 77.0 ± 10.1 79.7 ± 10.5 0.036
BMI (kg/m2) 22.9 ± 2.9 24.1 ± 3.1 25.6 ± 4.0 <0.001
Visceral fat area (cm2) 104.1 ± 46.8 126.1 ± 59.4 176.7 ± 77.3 <0.001
Subcutaneous fat area (cm2) 132.6 ± 40.8 143.7 ± 55.9 161.9 ± 76.0 0.064
HbA1c (%) 5.5 ± 0.2 5.9 ± 0.2 6.8 ± 1.1 <0.001
HbA1c (mmol/mol) 36.6 ± 2.1 41.0 ± 2.1 50.8 ± 11.6 <0.001
Glycated albumin (%) 11.0 ± 1.3 11.6 ± 1.5 15.5 ± 5.7 <0.001
Fasting glucose (mg/dL) 90.0 ± 8.1 96.6 ± 9.4 115.4 ± 28.5 <0.001
Postprandial glucose (mg/dL) 100.5 ± 14.1 118.4 ± 31.4 27.1 ± 58.6 <0.001
Fasting insulin (µIU/mL) 5.46 ± 3.18 7.06 ± 4.14 8.62 ± 7.14 0.002
Postprandial insulin (µIU/mL) 21.61 ± 16.55 35.13 ± 31.95 54.85 ± 53.23 <0.001
Fasting C‑peptide (ng/mL) 1.69 ± 0.61 2.15 ± 0.75 2.36 ± 1.12 <0.001
Postprandial C‑peptide (ng/mL) 5.29 ± 2.61 7.18 ± 3.54 7.81 ± 4.67 <0.001
HOMA‑IR 1.21 ± 0.73 1.70 ± 1.06 2.65 ± 2.40 <0.001
TyG 8.25 ± 0.57 8.50 ± 0.50 8.80 ± 0.63 <0.001
Adipo‑IR 25.93 ± 20.59 30.89 ± 23.76 37.53 ± 37.47 0.284
Total cholesterol (mg/dL) 191.4 ± 36.8 191.5 ± 38.1 166.6 ± 45.3 0.001
HDL cholesterol (mg/dL) 49.1 ± 11.8 49.9 ± 12.6 45.0 ± 11.7 0.018
LDL cholesterol (mg/dL) 114.9 ± 33.6 114.8 ± 33.6 96.8 ± 33.8 0.001
Fasting TG (mg/dL) 103.0 ± 71.0 116.2 ± 59.8 133.2 ± 73.2 0.055
Postprandial TG (mg/dL) 91.1 ± 71.7 107.6 ± 50.6 132.7 ± 84.4 0.138
Fasting FFA (µEq/L) 690.4 ± 380.4 621.4 ± 238.6 704.3 ± 305.4 0.298
Postprandial FFA (µEq/L) 171.5 ± 182.9 134.0 ± 104.1 191.8 ± 154.9 0.126
Lipoprotein(a) (mg/dL) 22.1 ± 24.1 23.4 ± 25.4 29.7 ± 34.2 0.359
Uric acid (mg/dL) 4.9 ± 1.3 5.5 ± 1.3 5.4 ± 1.1 <0.001
Antihypertensive medication user 10 (13.3) 42(20.5) 23 (37.7) 0.002
Statin user 6(7.9) 31(14.9) 20 (32.3) <0.001
Antidiabetic medication user NA NA 25 (41.0)
Metformin user NA NA 19 (31.1)
Sulfonylurea user NA NA 9 (14.8)
DPP4 inhibitor user NA NA 9 (13.1)
TZD user NA NA 5 (8.2)
Insulin user NA NA 5 (8.2)
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Relationship between myocardial glucose uptake 
and metabolic parameters
To assess the relationship between myocardial glucose 
uptake and metabolic parameters, univariate analysis was 
performed (Table  2). Myocardial glucose uptake corre-
lated negatively with BMI, HbA1c, fasting glucose, insu-
lin, C-peptide, fasting/postprandial TG, FFA. Moreover, 
statistically significant inverse correlations were found 
between myocardial glucose uptake and evidence of 
insulin resistance, on the basis of HOMA-IR (r = −0.15, 
p  =  0.011), Adipo-IR (r  =  −0.32, p  <  0.001), uric acid 
(r = −0.21, p < 0.001), and visceral fat areas (r = −0.26, 
p < 0.001), subcutaneous fat areas (r = −0.14, p = 0.025).
Multiple linear regression analysis was performed to 
determine whether myocardial glucose uptake was inde-
pendently associated with various factors of body com-
position in addition to age, sex, social habits such as 
drinking and smoking, use of antidiabetic medication and 
statin, systolic blood pressure (SBP) (Model 1), CACS 
and laboratory parameters in addition to the age and sex 
(Model 2), and variables derived from the basic models 
(Model 1 and 2; Model 3, Table 3). In the comprehensive 
model (Model 3), visceral fat area (β = −0.22, p = 0.018), 
fasting FFA (β = −0.39, p < 0.001), and uric acid levels 
(β = −0.21, p =  0.007) were independent determinants 
of myocardial glucose uptake after adjustment for effec-
tive parameters from Model 1 and 2.
Associations between myocardial glucose uptake, visceral 
adiposity, and type 2 diabetes
As shown in Table  4, multiple logistic regression analy-
ses were used to further investigate significant determi-
nants in relation to T2DM. After sequential adjustment 
for confounding covariates including age, sex, current 
drinker, current smoker, use of antihypertensive medica-
tions, BMI, fasting FFA, and uric acid (Model 4), patients 
with T2DM had significantly elevated ORs for decreased 
myocardial glucose uptake (OR 2.32, 95 % CI 1.02–5.26, 
p = 0.045) and increased visceral fat areas (OR 1.02, 95 % 
CI 1.00–1.03, p = 0.018).
Discussion
In this study, we firstly investigated fasting myocardial 
glucose uptake by using 18FDG-PET and visceral/subcu-
taneous adipose tissue areas by abdominal CT in a total 
of 346 individuals, who were stratified based on glucose 
tolerance (NGT, IFG, and T2DM). Our results demon-
strated that fasting myocardial glucose uptake was mark-
edly decreased in patients with T2DM compared to the 
other two groups. Reduced myocardial glucose uptake 
Fig. 1 Altered myocardial glucose uptake of [18F]‑fluorodeoxyglucose (18FDG) in subjects according to the glycemic status. Each subject has a 
median value within the highest tertile of myocardial glucose uptake for normal glucose tolerance (NGT), prediabetes, and type 2 diabetes mellitus 
(T2DM)
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was related with a greater visceral fat area, higher con-
centration of circulating FFA, and uric acids, which could 
be related to systemic insulin resistance. Furthermore, 
the alteration of myocardial glucose uptake was strongly 
associated with T2DM, in along with visceral adiposity.
Previously, hyperglycemia, hyperinsulinemia, and 
disturbances of carbohydrates, fatty acids, and protein 
metabolism have all been correlated with prediabe-
tes and T2DM [3, 22, 23]. Therefore, impaired glucose 
uptake and metabolism in not only the skeletal muscle, 
but also in the heart, which requires sources of energy 
mostly from FFA and glucose, could be correlated with 
insulin resistance for prediabetes and T2DM, contribut-
ing to the development of hyperglycemia [24]. The data 
of this study support that systemic insulin resistance is 
strongly related to decreased myocardial glucose uptake 
[25, 26]. The estimation of whole body and adipose tis-
sue insulin resistance by HOMA-IR and Adipo-IR all 
showed significant negative correlations with myocardial 
glucose uptake in this large number of study population. 
Although previous studies revealed that myocardial fatty 
acid metabolism increased with obesity and female sex 
[26, 27], relationship between visceral adiposity and myo-
cardial glucose uptake has not been studied yet. To note, 
this study demonstrates that greater visceral fat area, not 
subcutaneous is significantly associated with decreased 
myocardial glucose uptake as well as the presence of 
T2DM, even after adjustment of other confounding fac-
tors including sex and BMI. Visceral adipose tissue has 
proven to be causally linked to insulin resistance much 
greater than subcutaneous adipose tissue, by paracrine 
and endocrine effects from a set of cytokines, particularly 
high levels of tumor necrosis factor-alpha (TNF-α), low 
levels of adiponectin, increased macrophage accumula-
tion, and excess of circulating FFA [28–30]. These find-
ings are consistent with the results of the current study, 
showing that myocardial glucose uptake was significantly 
decreased, while visceral adiposity was increased with 
elevated levels of plasma FFA, in patients with T2DM.
Fig. 2 Box plot of myocardial glucose uptake according to glycemic 
status. The box represents the upper and lower quartiles. Each + and 
horizontal line in the box indicates the mean and median value of 
myocardial glucose uptake, respectively. The bar denotes 10–90 
percentiles. NGT normal glucose tolerance, T2DM type 2 diabetes 
mellitus
Table 2 Correlation between  myocardial glucose uptake 
and metabolic factors
Adipo-IR index of adipose tissue insulin resistance, BMI body mass index, DBP 
diastolic blood pressure, FFA free fatty acids, HOMA-IR Homeostasis model 
assessment of insulin resistance, HDL high density lipoprotein, LDL low density 
lipoprotein, SBP systolic blood pressure, TG triglycerides, TyG the product of 
fasting triglycerides and glucose levels
Variables r p
Age (years) −0.01 0.980
SBP (mmHg) −0.08 0.145
DBP (mmHg) −0.02 0.725
BMI (kg/m2) −0.17 0.002
Visceral fat area (cm2) −0.26 <0.001
Subcutaneous fat area (cm2) −0.14 0.025
HbA1c (%) −0.12 0.027
Glycated albumin (%) −0.01 0.896
Fasting glucose (mg/dL) −0.16 0.002
Postprandial glucose (mg/dL) −0.11 0.066
Fasting insulin (µIU/mL) −0.13 0.028
Postprandial insulin (µIU/mL) −0.11 0.069
Fasting C‑peptide (ng/mL) −0.18 0.003
Postprandial C‑peptide (ng/mL) −0.10 0.103
HOMA‑IR −0.15 0.011
TyG −0.16 0.004
Adipo‑IR −0.32 <0.001
Total cholesterol (mg/dL) −0.02 0.688
HDL cholesterol (mg/dL) 0.03 0.644
LDL cholesterol (mg/dL) 0.01 0.802
Fasting TG (mg/dL) −0.16 0.003
Postprandial TG (mg/dL) −0.23 0.003
Fasting FFA (µEq/L) −0.33 <0.001
Postprandial FFA (µEq/L) −0.19 0.020
Lipoprotein(a) (mg/dL) 0.05 0.378
Uric acid (mg/dL) −0.21 <0.001
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In agreement with previous studies, we showed that 
fasting FFA was an independent predictor for myocardial 
glucose uptake [9, 10]. There have been conflicting find-
ings on the relationship between the direct effect of myo-
cardial insulin resistance on myocardial glucose uptake 
and the independence of increased plasma FFA [9, 25]. 
For example, there were reports that serum FFA concen-
trations suppressed by acipimox, a potent nicotinic acid 
derivative, affected glucose uptake in the myocardium 
via inhibition of lipolysis [9], and FFA levels decreased by 
rosiglitazone therapy were associated with the improve-
ment in myocardial glucose uptake [31]. However, 
Yokoyama et al. showed that the whole body glucose dis-
posal rate (GDR) was independently related to myocar-
dial FDG uptake, whereas FFA was not [25]. The more 
prominent relation between GDR and myocardial FDG 
uptake than between myocardial FDG uptake and FFA 
in patients with diabetes suggested that insulin resist-
ance regulates the myocardial cellular glucose FFA cycle, 
the so-called Randle cycle [32], and/or levels of plasma 
FFA. In a similar manner, Hicks et  al. reported that the 
correlation between myocardial FDG uptake and GDR 
was greater than that between myocardial FDG uptake 
and FFA in diabetic patients [33]. In addition, the current 
data which visceral adiposity or uric acid as well as fast-
ing FFA was an independent determinant for myocardial 
glucose uptake, also suggest that not only direct effect of 
elevated fasting FFA concentration but also insulin resist-
ance may connect with myocardial metabolism.
Previous studies showed that in the normal heart under 
fasting conditions, FDG uptake showed variable myocar-
dial glucose uptake because FFA is a primary source of 
energy, whereas glucose utilization is relatively low for the 
myocardial oxidative metabolism compared to glucose-
loading conditions [34, 35]. However, in the T2DM heart, 
regulation of glucose metabolism differed from the nor-
mal heart, therefore prior studies showing that myocar-
dial FDG uptake was significantly decreased in diabetic 
patients compared to normal subjects are consistent with 
our results [8, 34]. The underlying mechanism behind 
association with systemic insulin resistance and myocar-
dial glucose metabolism has been still investigated. Car-
diac myocytes utilize glucose mostly via insulin-sensitive 
glucose transporters (GLUT4) that are responsible for 
more than 50  % of all glucose uptakes in the body [36], 
and reduced expression and mutations of GLUT4 have 
been associated with diabetes [37, 38]. Recent study 
showed that increased insulin receptor substrate 1 
Table 3 Analysis of myocardial glucose uptake associated with metabolic parameters
Model 1 adjusted for age, sex, current drinker, current smoker, use of antidiabetic medications, use of statin, SBP, BMI, and subcutaneous fat area, Model 2 adjusted 
for age, sex, coronary artery calcification score, fasting/postprandial glucose, C-peptide, insulin, FFA, TG, HbA1c, uric acid, Model 3 adjusted for age, sex, and variables 
derived from Model 1 and 2
BMI body mass index, FFA free fatty acids, SBP systolic blood pressure, TG triglycerides
R2 Model 1 Model 2 Model 3
0.081 0.282 0.297
Variables β p β p β p
Visceral fat area (cm2) −0.29 <0.001 – – −0.22 0.018
Fasting FFA (µEq/L) – – −0.39 <0.001 −0.39 <0.001
Uric acid (mg/dL) – – −0.26 <0.001 −0.21 0.007
Postprandial glucose (mg/dL) – – −0.18 0.020 – –
Postprandial TG (mg/dL) – – −0.24 0.001 – –
Table 4 Logistic regression analyses for related factors for type 2 diabetes
Model 1 unadjusted, Model 2 adjusted for age, sex, current drinker, current smoker, use of antihypertensive medications, Model 3 adjusted for age, sex, current drinker, 
current smoker, use of antihypertensive medications, BMI, and visceral fat area, Model 4 adjusted for age, sex, current drinker, current smoker, use of antihypertensive 
medications, BMI, visceral fat area, fasting FFA, and uric acid
BMI body mass index, CI confidence interval, FFA free fatty acids, OR odds ratio
Variables Model 1 Model 2 Model 3 Model 4
OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p
Myocardial glucose uptake 0.51 (0.34–0.76) 0.001 0.49 (0.31–0.77) 0.002 0.57 (0.33–0.98) 0.042 0.43 (0.19–0.98) 0.045
Visceral fat area (cm2) – – – – 1.01 (1.01–1.02) 0.013 1.02 (1.01–1.03) 0.018
Fasting FFA (µEq/L) – – – – – – 1.00 (0.99–1.00) 0.920
Uric acid (mg/dL) – – – – – – 0.82 (0.52–1.29) 0.389
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(IRS1)-phosphoinositide 3-kinase (PI3K) activity with a 
concurrent activation of the insulin receptor was occurred 
with a diminished translocation of GLUT4 to the sar-
colemmal membrane in the heart even in fasting status 
of diabetes. Also, the increase in expression of GLUT4 
trafficking and docking components turned out to be dys-
function of GLUT4 vesicles in diabetic heart [39]. There-
fore, whole body insulin resistance maybe connected 
with myocardial insulin resistance, in the condition of 
down-regulated sarcolemmal GLUT4, thus resulting in 
decreased fasting myocardial glucose uptake in this cur-
rent study.
In this study, patients with T2DM had relatively low 
levels of HbA1c (6.8 %) and a low proportion of antidia-
betic drug users (41.0 %), and most of them were newly 
diagnosed or well controlled diabetic patients. How-
ever, we found that myocardial glucose uptake showed a 
marked gradual decrease in patients with insulin resist-
ant prediabetes and even well controlled T2DM. The 
relationship between hyperglycemia and development 
of ischemic heart disease has been well known [40, 41], 
but the effects of diabetes on myocardial metabolism still 
remain uncertain [42, 43]. Several studies have reported 
that a chronic shift of myocardial substrate preference 
in the diabetic heart resulted in a prominent decrease in 
glucose and lactic acid oxidation, and an increase in fatty 
acid oxidation [4, 5]. The effects of diabetes on myocar-
dial metabolism are very complex, including systemic 
metabolic disturbances of hyperglycemia, increased FFA, 
down-regulation of glucose transporters, increased insuf-
ficient energy utilization of fatty acid oxidation, lipid 
accumulation, and lipid toxicity in cardiomyocytes [44, 
45]. Therefore, the current study results could emphasize 
the association of diabetes and myocardial metabolism in 
connection with insulin resistance, and suggest that ben-
eficial effects of an adequate glycemic control on myocar-
dial metabolic disturbances in diabetes. These metabolic 
disturbances may lead to diabetic cardiomyopathy, how-
ever, further studies of the relationship between myocar-
dial glucose uptake and cardiac function will be needed 
to determine the exact mechanisms [46–48].
This study had several distinguishable strengths. To our 
knowledge, it was the first study to investigate myocar-
dial glucose uptake using 18FDG-PET in the largest study 
population together with the subcutaneous and visceral 
adiposity by abdominal CT, a gold standard method for 
quantification, and determinations of other metabolic 
parameters like HOMA-IR and Adipose-IR, which eval-
uated whole body insulin sensitivity, according to the 
glycemic status. Second, because the induction of myo-
cardial ischemia could affect myocardial metabolism, 
we excluded patients not only having history of known 
coronary artery disease and heart failure but also having 
CACS over 400, who could have subclinical atherosclero-
sis [11]. Also, striking focal FDG uptake in the left ven-
tricle was investigated to exclude ischemic change on 
PET image analysis [17]. Therefore, as the incidence of 
coronary artery disease in patients with diabetes is higher 
compared to normal healthy people, asymptomatic sub-
jects with coronary artery disease could be excluded in 
this current study [49]. Finally, on PET image analysis, 
myocardial glucose uptake was estimated as ratio of max-
imum value of SUV in the myocardium and mean value 
of SUV in the liver. In FDG-PET for malignancy, the liver 
has been used as an internal standard for grading FDG 
uptake of whole body lesions because SUV in liver but 
not in other tissues stays stable over time even in patients 
with diffuse fatty liver disease when measured as a mean 
in the right lobe of the liver [19, 20, 50]. Also, the mean 
SUV of liver in the early images after injection (50–
70 min) as same as the present study shows no depend-
ency on blood glucose level [51]. In this current study, we 
obtained three mean SUVs of the right lobe of the liver, 
and used the values as comparators for increased FDG 
uptake in the heart. Therefore, the value of myocardial 
glucose uptake as ratio of maximum value of SUV in the 
myocardium and mean value of SUV in the liver is rela-
tively consistent and reliable in this study.
The current study also had several limitations. The 
cross-sectional study design was insufficient to deter-
mine a causal relationship in the development of 
impaired myocardial glucose uptake. In addition, we did 
not assess cardiac function in our participants; therefore, 
possible correlations between myocardial glucose uptake 
and cardiac function would be an important topic for 
future studies.
Conclusion
In conclusion, we confirmed that myocardial glucose 
uptake decreased in patients with T2DM, and demon-
strated that there were associations between alterations 
of myocardial glucose uptake and increased levels of free 
fatty acids, uric acid, and visceral adiposity, in terms of 
whole body insulin resistance. Importantly, alterations 
of myocardial glucose uptake were related with T2DM 
as well as visceral adiposity. Additional studies will be 
needed to confirm the relationships of alterations of 
myocardial glucose metabolism in T2DM and the devel-
opment of abnormal cardiac function.
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